Basic Trial Information
Trial Description
     Summary
     Further Trial Information
     Eligibility Criteria
Trial Contact Information

Basic Trial Information

Trial Description

Summary

RATIONALE: Giving chemotherapy drugs through an implanted port reduces the need for multiple needle sticks. It is not yet known whether one type of port is more effective than another in reducing infections and other side effects associated with long-term port use.

PURPOSE: This randomized clinical trial is comparing two types of ports in patients with cancer receiving intravenous chemotherapy.

Further Study Information

OBJECTIVES:

Primary

• To compare the rate of port failure, defined as the occurrence of port malfunction or port infection within 12 months after port insertion, in patients with cancer requiring long-term adjuvant intravenous chemotherapy undergoing insertion of a newly designed, FDA-approved Vortex® implantable vascular access port vs a conventional vascular access port.

Secondary

• To compare the rate of port malfunction or port infection at 6 and 12 months after port insertion.

• To compare the rate of central vein thrombosis at 6 and 12 months after port insertion.

• To compare the rate of port removal for any reason other than infection or occlusion at 6 and 12 months after port insertion.

• To compare the rate of termination of use of the indwelling port at 6 and 12 months after port insertion.

• To compare the death from all causes.

• To compare the incidence of port-related interventions at 6 and 12 months after port insertion.

OUTLINE: Patients are randomized to 1 of 2 intervention arms.

• Arm I: Patients undergo insertion of the Vortex® implantable vascular access port. Patients then receive standard chemotherapy.

• Arm II : Patients undergo insertion of a conventional vascular access port. Patients then receive standard chemotherapy.

All episodes of access to the port are documented for 12 months after port insertion. Information including the reason for port access and difficulty in access is collected. Complications, such as occlusion and infection, implant duration, and incidence of port-related interventions are assessed at 6 and 12 months after port insertion.

Eligibility Criteria

DISEASE CHARACTERISTICS:

• Diagnosis of malignancy requiring intravenous chemotherapy for ≥ 6 months

• Must undergo entire course of chemotherapy at the Mayo Clinic in Jacksonville, unless the outside treating institution agrees to submit the research data sheet to Mayo Clinic

• Scheduled time frame for regular use of the vascular access port ≥ 3 months after port insertion

PATIENT CHARACTERISTICS:

• Life expectancy ≥ 6 months

• No active skin condition implicating an elevated risk of local or systemic infectious or non-infectious complications, including any of the following:

• Current skin infection

• Cutaneous lymphoma

• Auto-immune disorders

• Active vasculitis

• Connective tissue diseases

• No known active infection requiring antibiotic therapy at the time of port implantation

• Patients without an active infection who are on chronic antibiotic suppressive therapy are eligible

• No concurrent illness requiring chronic anticoagulation

• Patients who develop other comorbidities requiring chronic anticoagulation during the study period are eligible

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics

Trial Contact Information

Trial Lead Organizations/Sponsors

Mayo Clinic Cancer Center

Albert G. Hakaim

Principal Investigator

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00607880
Information obtained from ClinicalTrials.gov on December 14, 2011

Back to Top